Inhibitory effect of linomide on lipopolysaccharide-induced proinflammatory cytokine tumor necrosis factor-alpha production in RAW264.7 macrophages through suppression of NF-κB, p38, and JNK activation

Immunology Letters

Volumn 114, Issue 2, 2007, Pages 81-85

  Xiao, Zhi Yong ^a   Zhou, Wen Xia ^a   Zhang, Yong Xiang ^a   Cheng, Jun Ping ^a   He, Jun Feng ^a   Yang, Ri Fang ^a   Yun, Liu Hong ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

JNK; Linomide; NF B; p38 kinase; RAW264.7; TNF

Indexed keywords

I KAPPA B KINASE BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; ROQUINIMEX; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; CELL LINE; CONSENSUS; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; IMMUNOBLOTTING; IN VITRO SELECTION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPORTER GENE;

ANIMALS; CELL LINE; ENZYME ACTIVATION; HYDROXYQUINOLINES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36549076451     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.09.001     Document Type: Article

References (36)

1. Bjork J., and Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 27 (1989) 319-321
2. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol 34 (1993) 654-660
3. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 90 (1993) 6400-6404
4. Zhu J., Diab A., Mustafa M., Levi M., Wahren B., Björk J., et al. Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats. J Neuro Sci 160 (1998) 113-120
5. Diab A., Michael L., Wahren B., Deng G.M., Björk J., Hedlund G., et al. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J Neuroimmunol 85 (1998) 146-154
6. Bai X.F., Shi F.D., Zhu J., Xiao B.G., Hedlund G., and Link H. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J Neuroimmunol 76 (1997) 177-184
7. Slavin S., Sidi H., Weiss L., Roesnman E., Kalland T., and Gross D. Linomide, a new treatment for autoimmune diseases: The potential in type 1 diabetes. Diab Metab Rev 9 (1993) 311-315
8. Weiss L., Barak V., Zeira M., Abdul-Hai A., Raibstein I., Reich S., et al. Cytokine production in linomide-treated NOD mice and the potential role of a Th1/Th2 shift on autoimmune and anti-inflammatory processes. Cytokine 19 (2002) 85-93
9. Dahlén E., Dawe K., Ohlsson L., Hall H., Hedse K., Annersten K., et al. Linomide inhibits insulitis and modulates cytokine production in pancreatic islets in the nonobese diabetic mouse. Int Immunopharmacol 3 (2003) 17-30
10. Tarkowski A., Gurnarsson K., Nilsson L.A., Lindholm L., and Stalkandske T. Successful treatment of autoimmunity in MRL/l mice with LS-2616, a new immunomodulator. Arth Rheum 29 (1986) 1405-1409
11. Tarkowski A., Gurnarsson K., and Stalhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZB × NZW) F1 hybrid mice. Immunology 59 (1986) 589
12. Lehmann D., Karussis D.M., Fluresco D., Mizrachi-Koll R., Ovadia H., Shezen E., et al. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J Neuroimmunol 74 (1997) 102-110
13. Morrison D.C., and Ryan J.L. Endotoxins and disease mechanisms. Annu Rev Med 38 (1987) 417-432
14. Beutler B., and Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 57 (1988) 505-518
15. Heumann D., and Glauser M.P. Anticytokine strategies for the treatment of septic shock: relevance of animal models. Curr Top Microbiol 216 (1996) 299-311
16. Vilcek J., and Lee T.H. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 266 (1991) 7313-7316
17. Comerford L.W., and Bickston S.J. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am 33 (2004) 387-406
18. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
19. He J.F., Yun L.H., Yang R.F., Xiao Z.Y., Cheng J.P., Zhou W.X., et al. Design, synthesis, and biological evaluation of novel 4-hydro-quinoline-3-carboxamide derivatives as an immunomodulator. Bioorg Med Chem Lett 15 (2005) 2980-2985
20. Zhang J.Y., Shen B.F., Li Y., and Sun Y.X. STAT3 exerts two-way regulation in the biological effects of IL-6 in M1 leukemia cells. Leuk Res 25 (2001) 463-472
21. Fujihara M., Muroi M., Tanamoto K., Suzuki T., Azuma H., and Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 100 (2003) 171-194
22. Kuroiw T., and Lee E.G. Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophages in the amplification of the inflammatory process in the kidney. Lupus 7 (1998) 597-603
23. Hill G.S., Delahousse M., Nochy D., Remy P., Mignon F., Mery J.P., et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 59 (2001) 304-316
24. Aringer M., and Smolen J.S. Cytokine expression in lupus kidneys. Lupus 14 (2005) 13-18
25. Ghosh S., May M.J., and Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16 (1998) 225-260
26. Zheng L., Sinniah R., and I-Hong Hsu S. Renal cell apoptosis and proliferation may be linked to nuclear factor-κ B activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum Pathol 37 (2006) 637-647
27. Ban H.S., Suzuki K., Lim S.S., Jung S.H., Lee S., Ji J., et al. Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase and tumor necrosis factor-α by 2′-hydroxychalcone derivatives in RAW264.7 cells. Biochem Pharmacol 67 (2004) 1549-1557
28. Piette J., Piret B., Bonizzi G., Schoonbroodt S., Merville M.P., Legrand-Poels S., et al. Multiple redox regulation in NF-κB transcription factor activation. Biol Chem 378 (1997) 1237-1245
29. Ziegler-Heitbrock H.W., Sternsdorf T., Liese J., Belohradsky B., Weber C., Wedel A., et al. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol 151 (1993) 6986-6993
30. Abdul-Hai A., Hershkoviz R., Weiss L., Lider O., and Slavin S. Effect of Linomide on adhesion molecules, TNF-α, nitrogen oxide, and cell adhesion. Int Immunopharmacol 5 (2005) 231-239
31. Jordan J.D., Landau E.M., and Iyengar R. Signaling networks: the origins of cellular multitasking. Cell 103 (2000) 193-200
32. Ip Y.T., and Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 10 (1998) 205-219
33. + T cells to Th1 cells requires MAP kinase JNK2. Immunity 7 (1998) 575-585
34. Rincón M., Enslen H., Raingeaud J., Recht M., Zapton T., Su M.S.-S., et al. Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 17 (1998) 2817-2829
35. Rus V., Svetic A., Nguyen P., Gause W., and Via C. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol 155 (1995) 2396-2406
36. Bruijn J.A., Bergijk E.C., de Heer E., Fleuren G.J., and Hoedemaeker P.J. Induction and progression of experimental lupus nephritis: exploration of a pathogenetic pathway. Kidney Int 41 (1992) 5-13